2. Search Result
Search Result
Results for "

MAGL inhibitor

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-111538
    MAGL-IN-1

    		MAGL Cancer
    MAGL-IN-1 is a potent, selective, reversible and competitive inhibitor of MAGL, with an IC50 of 80 nM. MAGL-IN-1 exhibits anti-proliferative effects against human breast, colorectal, and ovarian cancer cells. MAGL-IN-1 blocks MAGL in cell-based as well as in vivo assays .
    MAGL-IN-1
  • HY-132310
    MAGL-IN-4

    		MAGL Neurological Disease
    MAGL-IN-4 is an orally active, selective and reversible monoacylglycerol lipase (MAGL) inhibitor with an IC50 of 6.2 nM. MAGL-IN-4 can penetrate the blood-brain barrier (BBB). MAGL-IN-4 enhances endocannabinoid signaling mostly by the increase in the level of 2-AG via selective MAGL inhibition in the brain .
    MAGL-IN-4
  • HY-157040
    MAGL-IN-9

    		MAGL Inflammation/Immunology
    MAGL-IN-9 (compound 16) is a selective and reversible MAGL inhibitor with IC50 2.7 nM .
    MAGL-IN-9
  • HY-124576
    ABD-1970

    		MAGL Neurological Disease
    ABD-1970 is a selective monoacylglycerol lipase (MAGL) inhibitor with IC50s of 15 nM and 29 nM for human and mouse MAGL, respectively. ABD-1970 shows selectivity for MGLL over other members of the serine hydrolase class. ABD-1970 has the potential for the study of neurological disorders .
    ABD-1970
  • HY-124378
    MAGL-IN-17

    		MAGL Inflammation/Immunology
    MAGL-IN-17 (Compound ) is an inhibitor for MAGL with a Ki of 0.4 μM. MAGL-IN-17 inhibits mouse MAGL and rat MAGL with IC50 of 0.18 and 0.24 μM. MAGL-IN-17 exhibits anti-inflammatory activity in mouse experimental autoimmune encephalitis models .
    MAGL-IN-17
  • HY-157042
    MAGL-IN-11

    		MAGL Inflammation/Immunology Cancer
    MAGL-IN-11 (compound 29) is a selective and reversible MAGL inhibitor. MAGL-IN-11 has the potential to study inflammation, cancer and antioxidants .
    MAGL-IN-11
  • HY-168145
    MAGL-IN-19

    		MAGL Cancer
    MAGL-IN-19 (compund 7o) is a highly potent and selective MAGL inhibitor .
    MAGL-IN-19
  • HY-145945
    MAGL-IN-6

    		MAGL Neurological Disease
    MAGL-IN-6 is a potent MAGL inhibitor with an IC50 of 4.71 nM. MAGL-IN-6 can be used for neurological disorders research (WO2020065613A1; example 234) .
    MAGL-IN-6
  • HY-168032
    MAGL-IN-18

    		MAGL Inflammation/Immunology
    MAGL-IN-18 (compound 118) is a potent Monoacylglycerol lipase (MAGL) inhibitor with an IC50 of 0.03 nM .
    MAGL-IN-18
  • HY-143263
    FAAH/MAGL-IN-1

    		FAAH MAGL Neurological Disease
    FAAH/MAGL-IN-1 (compound SIH 3) is a potent FAAH and MAGL inhibitor with IC50s of 31 nM and 29 nM, respectively. FAAH/MAGL-IN-1 has the potential for the research of neuropathic pain .
    FAAH/MAGL-IN-1
  • HY-157041
    MAGL-IN-10

    		MAGL Cancer
    MAGL-IN-10 is areversible monoacylglycerol lipase (MAGL) inhibitor with very good ADME properties and low in vivo toxicity.MAGL-IN-10 can be used for the research ofcancer, neurological disorders and inflammatory pathologies .
    MAGL-IN-10
  • HY-146342
    FAAH/MAGL-IN-3

    		FAAH MAGL Neurological Disease
    FAAH/MAGL-IN-3 (Compound 10) is an irreversible fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) dual inhibitor with IC50 values of 179 and 759 nM against FAAH and MAGL, respectively. FAAH/MAGL-IN-3 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability .
    FAAH/MAGL-IN-3
  • HY-168459
    MAGL-IN-21

    		MAGL Neurological Disease
    MAGL-IN-21 (Compound (S)-6) is a selective inhibitor for monoacylglycerol lipase (MAGL) with an IC50 of 1.59 nM .
    MAGL-IN-21
  • HY-157038
    MAGL-IN-8

    		MAGL Inflammation/Immunology
    MAGL-IN-8 (compound 13) is a reversible monoacylglycerol lipase (MAGL) inhibitor, with an IC50 of 2.5 ± 0.4 nM for hMAGL .
    MAGL-IN-8
  • HY-162305
    MAGL-IN-15

    		MAGL Neurological Disease
    MAGL-IN-15 (Compound 6) is a MAGL inhibitor that can be used in the research of diseases and disorders related to the regulation of endocannabinoid system signaling activities .
    MAGL-IN-15
  • HY-169239
    MAGL-IN-20

    		MAGL Cancer
    MAGL-IN-20 (compound ±34) is a reversible monoacylglycerol lipase (MAGL) inhibitor. MAGL-IN-20 exhibits appreciable antiproliferative activities against several cancer cells, including H460, HT29, CT-26, Huh7 and HCCLM-3. .
    MAGL-IN-20
  • HY-162315
    MAGL-IN-16

    		MAGL Neurological Disease
    MAGL-IN-16 (compound 27) is an oral active, selective and reversible MAGL inhibitor with the IC50 value of 10.3 nM. MAGL-IN-16 can increase the level of 2-AG and shows antidepressant effect in mouse depressed model caused by chronic restraint stress .
    MAGL-IN-16
  • HY-163202
    MAGL-IN-13

    		MAGL Calcium Channel Neurological Disease Cancer
    MAGL-IN-13 (compound (3R, 4S) - 5v) is a selective, irreversible inhibitor for MAGL,with IC50 values of 0.026, 0.021 and 0.24 nM for mMAGL, hMAGL and rMAGL, respectively. MAGL-IN-13 can penetrant blood brain barrier. .
    MAGL-IN-13
  • HY-173296
    MAGL-IN-222

    		Lipase Cancer
    MAGL-IN-222 (Compound ZQ-7) is a covalent inhibitor targeting monoacylglycerol lipase (MAGL) with an IC50 of 42.31 μM. MAGL-IN-222 can reduce the breakdown of 2-arachidonoylglycerol (2-AG) and increase the intracellular 2-AG level, thereby inhibiting the proliferation and migration of MDA-MB-231 breast cancer cells. MAGL-IN-222 can be used in the research of breast cancer and other related diseases .
    MAGL-IN-222
  • HY-162304
    MAGL-IN-14

    		MAGL Neurological Disease
    MAGL-IN-14 (compound 2) is a potent inhibitor of MAGL, with IC50 of 0.00289 μM and 0.002 μM in HEK293 and PC3 cells, respectively .
    MAGL-IN-14
  • HY-12332
    JW 642
    2 Publications Verification

    		 MAGL Neurological Disease
    JW 642 is a potent inhibitor of monoacylglycerol lipase (MAGL) that displays IC50 values of 7.6, 14, and 3.7 nM for inhibition of MAGL in mouse, rat, and human brain membranes, respectively.
    JW 642
  • HY-143264
    FAAH/MAGL-IN-2

    		FAAH MAGL Neurological Disease
    FAAH/MAGL-IN-2 is a potent, reversible, orally active, and cross the blood-brain barrier FAAH and MAGL inhibitor with IC50s of 11 nM and 36 nM (Kis of 28 nM and 60 nM), respectively . FAAH/MAGL-IN-2 has the potential to research neuropathic pain without causing locomotion impairment .
    FAAH/MAGL-IN-2
  • HY-111512
    PF-06795071

    		MAGL Neurological Disease Inflammation/Immunology
    PF-06795071 is a potent and selective covalent MAGL inhibitor with an IC50 of 3 nM .
    PF-06795071
  • HY-15249
    JZL 184
    5 Publications Verification

    		 MAGL Neurological Disease
    JZL 184 is a potent, selective and irreversible MAGL inhibitor that blocks 2-Arachidonoylglycerol (2-AG) hydrolysis in brain membranes (IC50 of 8 nM). JZL 184 displays >300-fold selectivity for MAGL over FAAH .
    JZL 184
  • HY-119283
    CAY10499
    1 Publications Verification

    MAGL-IN-5

    		 MAGL FAAH SARS-CoV Influenza Virus Infection Metabolic Disease Inflammation/Immunology
    CAY10499 (MAGL-IN-5) is a non-selective lipase inhibitor with IC50 values of 144 nM and 14 nM for monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), respectively. Additionally, CAY10499 exhibits anti-inflammatory and antiviral activities .
    CAY10499
  • HY-136562
    N-Arachidonyl maleimide

    		MAGL Metabolic Disease
    N-Arachidonyl maleimide is a potent, irreversible inhibitor of monoacylglycerol lipase (MAGL) with an IC50 value of 140 nM .
    N-Arachidonyl maleimide
  • HY-118158
    FAAH/MAGL-IN-4

    		FAAH Neurological Disease
    FAAH/MAGL-IN-4 (Compound 13) is a potent fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL) inhibitor with IC50s of 9.1 nM and 7.9 μM, respectively. FAAH/MAGL-IN-4 can be used for the research of pain and CNS disorders .
    FAAH/MAGL-IN-4
  • HY-77491
    FAAH/MAGL-IN-5

    		FAAH MAGL Neurological Disease
    AM6701 is a potent FAAH/MAGL inhibitor (equipotent inhibitory IC50: 1.2 nM) with neuroprotective effects .
    FAAH/MAGL-IN-5
  • HY-18977
    KML29
    2 Publications Verification

    		 MAGL Metabolic Disease Inflammation/Immunology
    KML29 is an extremely selective, orally active and irreversible MAGL inhibitor, with IC50 values of 15 nM, 43 nM and 5.9 nM for mouse, rat and human MAGL, respectively. KML29 exhibits minimal cross-reactivity toward other central and peripheral serine hydrolases, including no detectable activity against FAAH .
    KML29
  • HY-108613
    JJKK 048
    1 Publications Verification

    		 MAGL Neurological Disease Cancer
    JJKK 048 is a highly selective and potent monoacylglycerol lipase (MAGL) inhibitor with IC50 values of 214 pM, 275 pM and 363 pM for human, rat, and mouse MAGL. JJKK 048 displays low cross-reactivity with other endocannabinoid targets. JJKK 048 can be used in the research of diseases such as cancer, neurodegenerative diseases, and pain .
    JJKK 048
  • HY-117632
    Elcubragistat
    1 Publications Verification

    ABX-1431

    		 MAGL Neurological Disease
    Elcubragistat (ABX-1431) is a highly potent, selective, and orally available, CNS-penetrant monoacylglycerol lipase (MAGL) inhibitor with an IC50 of 14 nM.
    Elcubragistat
  • HY-103339
    VDM11

    		FAAH MAGL Neurological Disease
    VDM11 is a potent and selective anandamide membrane transporter (AMT) inhibitor . VDM11 inhibits FAAH and MAGL and may act as an alternative FAAH substrate .
    VDM11
  • HY-15250
    JZL195
    4 Publications Verification

    		 FAAH MAGL Autophagy Neurological Disease
    JZL195 is a selective and efficacious dual fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitor with IC50s of 2 and 4 nM, respectively .
    JZL195
  • HY-103463
    SA57

    		FAAH MAGL Neurological Disease
    SA57 is a potent, selective FAAH inhibitor with IC50s of 3.2 nM and 1.9 nM for mouse and human FAAH. SA57 also inhibits the 2-arachidonoylglycerol hydrolases MAGL (IC50s of 410 nM and 1.4 μM for mouse and human MAGL) and mouse α/β-hydrolase domain-containing protein 6 (mABHD6; IC50 of 850 nM), but not other brain serine hydrolases .
    SA57
  • HY-150702
    MAGLi 432

    		MAGL Neurological Disease Inflammation/Immunology
    MAGLi 432 is a non-covalent, potent, highly selective, and reversible MAGL inhibitor. MAGLi 432 binds with high affinity to the MAGL active site, with IC50 values of 4.2 nM (human enzyme) and 3.1 nM (mouse enzyme). MAGLi 432 can be used in the research of chronic inflammation, blood–brain barrier dysfunction, neurological disorders such as multiple sclerosis, Alzheimer’s disease and Parkinson’s disease .
    MAGLi 432
  • HY-121422
    JZP-361

    		MAGL Histamine Receptor Inflammation/Immunology
    JZP-361 is a potent, reversible and selective inhibitor of human recombinant MAGL (hMAGL) with an IC50 of 46 nM. JZP-361 also shows antihistaminergic activities and can be used for asthma research .
    JZP-361
  • HY-163733
    AKU-005

    		FAAH MAGL Neurological Disease Inflammation/Immunology
    AKU-005 is a FAAH and MAGL dual inhibitor with IC50 values of 63, 389 nM for rat and human FAAH, respectively. AKU-005 has the potential for the research of trigeminal hyperalgesia .
    AKU-005
  • HY-116143
    MAGL-IN-12

    		MAGL Metabolic Disease
    SAR127303 is an orally active, selective, competitive monoacylglycerol lipase (MAGL) covalent inhibitor with IC50s of 3.8 nM and 29 nM for mouse and human MAGL, respectively. SAR127303 potently elevates hippocampal levels of 2-AG in mice. SAR127303 decreased long term potentiation (LTP) of CA1 synaptic transmission and acetylcholine release in the hippocampus. SAR127303 produces antinociceptive effects in assays of inflammatory and visceral pain. SAR127303 slows down epileptogenesis .
    MAGL-IN-12
  • HY-121476
    Arachidonoyl Serinol

    		MAGL Neurological Disease
    Arachidonoyl Serinol, an endogenous cannabimimetic metabolite, is an inhibitor of monoacylglycerol lipase (MAGL). Arachidonoyl Serinol inhibits the hydrolysis of [ 3H]2-oleoylglycerol and [ 3H]anandamide with IC50s of ～70 μM .
    Arachidonoyl Serinol
  • HY-120560
    OMDM169

    		MAGL Neurological Disease
    OMDM169 is a potent and selective monoacylglycerol lipase (MAGL) inhibitor with activity to increase 2-AG levels. OMDM169 exerts analgesic activity through indirect activation of cannabinoid receptors. The effective concentration of OMDM169 is 0.13 μM .
    OMDM169
  • HY-133130
    JNJ-42226314

    		MAGL Neurological Disease
    JNJ-42226314 is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy in models of neuropathic and inflammatory pain .
    JNJ-42226314
  • HY-117474
    MJN110
    3 Publications Verification

    		 MAGL Neurological Disease
    MJN110 is an orally active and selective monoacylglycerol lipase (MAGL) inhibitor with IC50s of 9.1 nM and 2.1 nM for hMAGL and 2-arachidonoylglycerol (2-AG), respectively . MJN110 produces opioid-sparing effects and displays strong antihyperalgesic activity .
    MJN110
  • HY-139182
    MAGL-IN-3

    		Endogenous Metabolite Metabolic Disease
    CAY10762 is an inhibitor of monoacylglycerol lipase (MAGL; IC50=34.1 nM). It reduces hydrogen peroxide-induced lactate dehydrogenase (LDH) release from Neuro2a cells when used at a concentration of 1 μM. CAY10762 (10 mg/kg) increases levels of 2-arachidonoyl glycerol in mouse brain.
    MAGL-IN-3
  • HY-152152
    JZP-MA-13

    		MAGL Neurological Disease
    JZP-MA-13 is a selective α/β-hydrolase domain 6 (ABHD6) inhibitor with an IC50 of 392 nM. JZP-MA-13 shows no inhibition of MAGL, ABHD12, FAAH, or other serine hydrolases. JZP-MA-13 is a positron emission tomography (PET) ligand for in vivo imaging of the ABHD6 .
    JZP-MA-13
  • HY-120851
    O-7460

    		DAGL Cannabinoid Receptor Metabolic Disease
    O-7460 is a potent and selective DAGLα inhibitor, with an IC50 of 0.69 μM. O-7460 shows selectivity over onoacylglycerol lipase (MAGL), human CB1 and CB2 cannabinoid receptors. O-7460 can decrease HFD-caused an up-regulation of 2-AG levels .
    O-7460
  • HY-130311
    2-Linoleoyl glycerol

    2-Monolinolein; 2-Monolinoleoylglycerol

    		 Cannabinoid Receptor Neurological Disease
    2-Linoleoyl glycerol (2-Monolinolein; 2-Monolinoleoylglycerol) is a monoacylglycerol that is an antagonist and partial agonist at the type 1 cannabinoid CB1 receptor. The potency of 2-Linoleoyl glycerol can be enhanced by JZL195 (HY-15250), an inhibitor of FAAH and MAGL, and inhibited by the CB1 antagonist AM251 (HY-15443) and Cannabidiol. As a CB1 antagonist, 2-Linoleoyl glycerol does not enhance, but only attenuates, the activity of the CB1/CB2 receptor ligands cannabinoids (AEA) and 2-arachidonoylglycerol (2-AG) .
    2-Linoleoyl glycerol

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: